February 11, 2021

SARS-CoV-2 Antibody Prevalence in England Following the First Peak of the Pandemic

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): immunity, testing

A large serosurvey in England (REACT-2 Study) estimated the nationwide seroprevalence of SARS-CoV-2 to be 6%, corresponding to an estimated 3.4 million people with prior infection. Seroprevalence was determined from a representative cohort of over 100,000 adults (>18 years old). Prevalence was 2- to 3-fold higher among healthcare workers compared with non-essential workers, and higher among Black or South Asian adults compared to white adults, although age- and sex-specific infection fatality ratios were similar across ethnicities.

Ward et al. (Feb 10, 2021). SARS-CoV-2 Antibody Prevalence in England Following the First Peak of the Pandemic. Nature Communications. https://doi.org/10.1038/s41467-021-21237-w